PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.92%
Negative revenue growth while MRVL stands at 19.52%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.87%
Negative gross profit growth while MRVL is at 12.42%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.18%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-3.45%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
25.02%
Dividend growth of 25.02% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-7.05%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-9.93%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
66.42%
10Y revenue/share CAGR under 50% of MRVL's 513.47%. Michael Burry would suspect a lasting competitive disadvantage.
96.86%
5Y revenue/share CAGR under 50% of MRVL's 486.08%. Michael Burry would suspect a significant competitive gap or product weakness.
41.72%
3Y revenue/share CAGR under 50% of MRVL's 119.43%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
241.13%
Positive long-term OCF/share growth while MRVL is negative. John Neff would see a structural advantage in sustained cash generation.
127.23%
Positive OCF/share growth while MRVL is negative. John Neff might see a comparative advantage in operational cash viability.
37.02%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
401.02%
Net income/share CAGR above 1.5x MRVL's 73.47% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
252.29%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
93.61%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
91.65%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
10.40%
Below 50% of MRVL's 26.57%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-4.05%
Negative 3Y equity/share growth while MRVL is at 26.43%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
361.20%
Dividend/share CAGR of 361.20% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
355.42%
Dividend/share CAGR of 355.42% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
294.10%
3Y dividend/share CAGR of 294.10% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-13.89%
Firm’s AR is declining while MRVL shows 11.58%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.21%
Inventory is declining while MRVL stands at 8.57%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-7.70%
Negative asset growth while MRVL invests at 16.02%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-7.50%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-6.09%
Our R&D shrinks while MRVL invests at 46.07%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.63%
We cut SG&A while MRVL invests at 22.06%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.